Cancer Institute A national cancer institute
designated cancer center

Susan M. Swetter, MD

Publication Details

  • Current management of melanoma: Benefits of surgical staging and adjuvant therapy JOURNAL OF SURGICAL ONCOLOGY McMasters, K. M., Swetter, S. M. 2003; 82 (3): 209-216


    Issues regarding appropriate management of stage I to III melanoma are addressed. Accurate surgical staging is critical to identifying patients who can benefit from therapeutic lymph node dissection and adjuvant therapy. Patients with primary tumors > or = 1 mm thick are appropriate candidates for sentinel lymph node biopsy, and node-positive patients benefit from therapeutic lymphadenectomy. Although the overall survival benefit of high-dose interferon has been questioned, the weight of evidence supports the use of adjuvant therapy in patients with stage IIB and III disease.

    View details for DOI 10.1002/jso.10216

    View details for Web of Science ID 000181294400013

    View details for PubMedID 12619066

Stanford Medicine Resources:

Footer Links: